Tempus AI up after FDA issues draft guidance on AI use in drug decision making

The FDA has issued draft guidance to provides recommendations to sponsors and other interested parties on the use of artificial intelligence to produce information or data intended to support regulatory decision making regarding safety, effectiveness, or quality for drugs, stating that the draft guidance, when finalized, will “represent the current thinking of the Food and Drug Administration on this topic.” The FDA noted that the guidance document is “being distributed for comment purposes only” and that comments and suggestions regarding the draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. In morning trading following the publication of the notice, shares of Tempus AI (TEM) are up $2.05, or 5%, to $40.30.